Aclarion, Inc. (LS:A412BH) Financings
Financings
| Raise | Date |
|---|---|
| Common stock Closed: US$10.4M raised · US$5.18 a share · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) | Jan 13, 2026 |
| Registered direct offering of common stock Closed: US$2.5M raised | Oct 14, 2025 |
| Registered direct offering of common stock Announced: about US$4.7M · US$9.25 a share · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) Use of proceeds: Market development and clinical evidence, product development and quality, general and administration support, and general corporate purposes | Jan 30, 2025 |
| Public offering of common stock and pre-funded warrants with series A and series B common warrants Closed: US$14.4M raised · US$0.1 a share · Warrants at US$0.2 · Dawson James Securities, Inc. Dealers: Dawson James Securities, Inc. (lead) Use of proceeds: Redeem all outstanding Series B Preferred Stock; build out product platforms, expand sales and marketing, G&A and general corporate purposes | Jan 17, 2025 |